Revelation Biosciences, Inc. financial data

Symbol
REVB, REVBW on Nasdaq
Location
4660 Lajolla Village Drive, Suite 100, San Diego, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 8, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 261 % +34%
Debt-to-equity 61.3 % -41.5%
Return On Assets -149 % -25%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.7M shares +3.42%
Common Stock, Shares, Outstanding 1.53M shares -6.62%
Entity Public Float 3.13M USD -57.2%
Common Stock, Value, Issued 1.54K USD -6.57%
Weighted Average Number of Shares Outstanding, Basic 803K shares +2256%
Weighted Average Number of Shares Outstanding, Diluted 803K shares +2256%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 3.61M USD -25.1%
General and Administrative Expense 4.49M USD -4.48%
Operating Income (Loss) -8.11M USD +14.9%
Nonoperating Income (Expense) -356K USD +94.4%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -8.46M USD +46.8%
Earnings Per Share, Basic 188 USD/shares +97.2%
Earnings Per Share, Diluted 188 USD/shares +97.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 5.17M USD -57.1%
Assets, Current 5.36M USD -56.1%
Property, Plant and Equipment, Net 35.2K USD -50.3%
Assets 5.4M USD -56%
Accounts Payable, Current 829K USD -35.3%
Accrued Liabilities, Current 740K USD -91.3%
Liabilities, Current 1.57M USD -85.9%
Liabilities 1.57M USD -85.9%
Retained Earnings (Accumulated Deficit) -45M USD -23.2%
Stockholders' Equity Attributable to Parent 3.83M USD +235%
Liabilities and Equity 5.4M USD -56%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.79M USD +1.54%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 1.53M shares -6.62%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 5.17M USD -57.1%
Deferred Tax Assets, Valuation Allowance 14.9M USD +42%
Deferred Tax Assets, Gross 14.9M USD +42%
Depreciation 28.9K USD +15.3%
Lessee, Operating Lease, Liability, to be Paid 10.7K USD
Property, Plant and Equipment, Gross 151K USD +14.5%
Deferred Tax Assets, Operating Loss Carryforwards 10.9M USD +50.4%
Preferred Stock, Shares Issued 0 shares
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 48.8M USD +29.6%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 329K USD +156%